Tamayo Louis Edward
SEC insider (Form 3/4/5 filer). CIK 0002083206. Chief Financial Officer at Lexeo Therapeutics, Inc. (LXEO). 6 reported Form 4/5 transactions since Sep 2024; latest on Sep 24, 2026. Located in NEW YORK, NY.
Companies Tamayo Louis Edward has filed insider reports for
- Lexeo Therapeutics, Inc. (LXEO): Officer, Chief Financial Officer
Tamayo Louis Edward
CIK: 0002083206
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Lexeo Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Sep 24, 2026LXEO
Lexeo Therapeutics, Inc.
AwardDirectStock Option (right to buy)
54.8K shares- - Aug 18, 2026LXEO
Lexeo Therapeutics, Inc.
SaleDirect4.1K shares at avg. $4.91$20K - Jul 1, 2026LXEO
Lexeo Therapeutics, Inc.
SaleDirect4.6K shares at avg. $4.49$21K - Jun 29, 2026LXEO
Lexeo Therapeutics, Inc.
AwardDirect12K shares- - Feb 4, 2026LXEO
Lexeo Therapeutics, Inc.
AwardDirect44.7K shares- - Aug 29, 2025LXEO
Lexeo Therapeutics, Inc.
AwardDirect45K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 24, 2026 | LXEO Lexeo Therapeutics, Inc. | Award Stock Option (right to buy) | 54,750 | - | - | Direct |
| Aug 18, 2026 | LXEO Lexeo Therapeutics, Inc. | Sale | 4,117 | $4.91 | $20,203 | Direct |
| Jul 1, 2026 | LXEO Lexeo Therapeutics, Inc. | Sale | 4,641 | $4.49 | $20,838 | Direct |
| Jun 29, 2026 | LXEO Lexeo Therapeutics, Inc. | Award | 12,000 | - | $0 | Direct |
| Feb 4, 2026 | LXEO Lexeo Therapeutics, Inc. | Award | 44,665 | - | $0 | Direct |
| Aug 29, 2025 | LXEO Lexeo Therapeutics, Inc. | Award | 45,000 | - | - | Direct |
1-6 of 6 transactions